[go: up one dir, main page]

AU2001290860A1 - Spas-1 cancer antigen - Google Patents

Spas-1 cancer antigen

Info

Publication number
AU2001290860A1
AU2001290860A1 AU2001290860A AU9086001A AU2001290860A1 AU 2001290860 A1 AU2001290860 A1 AU 2001290860A1 AU 2001290860 A AU2001290860 A AU 2001290860A AU 9086001 A AU9086001 A AU 9086001A AU 2001290860 A1 AU2001290860 A1 AU 2001290860A1
Authority
AU
Australia
Prior art keywords
spas
cancer antigen
antigen
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001290860A
Inventor
James P. Allison
Marcella Fasso
Nilabh Shastri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California
University of California Berkeley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California Berkeley filed Critical University of California
Publication of AU2001290860A1 publication Critical patent/AU2001290860A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001290860A 2000-09-21 2001-09-13 Spas-1 cancer antigen Abandoned AU2001290860A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23447200P 2000-09-21 2000-09-21
US60/234,472 2000-09-21
PCT/US2001/028621 WO2002024739A2 (en) 2000-09-21 2001-09-13 Spas-1 cancer antigen

Publications (1)

Publication Number Publication Date
AU2001290860A1 true AU2001290860A1 (en) 2002-04-02

Family

ID=22881527

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001290860A Abandoned AU2001290860A1 (en) 2000-09-21 2001-09-13 Spas-1 cancer antigen

Country Status (5)

Country Link
US (1) US20020150588A1 (en)
EP (1) EP1320602A2 (en)
AU (1) AU2001290860A1 (en)
CA (1) CA2460014A1 (en)
WO (1) WO2002024739A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3925413B2 (en) * 2003-01-16 2007-06-06 住友化学株式会社 Iodine polarizing film, method for producing the same, and polarizing plate using the same
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
EP1592442A2 (en) * 2003-02-06 2005-11-09 Cerus Corporation Modified free-living microbes, vaccine compositions and methods of use thereof
WO2004110481A2 (en) * 2003-02-06 2004-12-23 Cerus Corporation Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
WO2008094188A2 (en) 2006-07-17 2008-08-07 Anza Therapeutics, Inc. Methods and compositions using listeria for enhancing immunogenicity by prime boost
US9161974B2 (en) 2010-05-23 2015-10-20 Aduro Biotech, Inc. Methods and compositions using listeria for adjuvant treatment of cancer
US9835624B2 (en) 2011-05-02 2017-12-05 The Regents Of The University Of California Compositions and methods for detecting mycobacterium
CA2876150A1 (en) 2012-06-08 2013-12-12 The Johns Hopkins University Compostions and methods for cancer immunotherapy
SG10201610161UA (en) 2012-11-06 2017-01-27 Aduro Biotech Inc Facultatively attenuated bacterial species and methods of preparation and use thereof
CA2886456A1 (en) 2012-12-13 2014-06-19 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
JP2016503655A (en) 2012-12-27 2016-02-08 アデュロ バイオテック，インコーポレイテッド Signal peptide fusion partner facilitating expression of the antigenic sequence of Listeria, its preparation method and its use
ES2822584T3 (en) 2013-05-03 2021-05-04 Univ California Induction of cyclic dinucleotides of type I interferon
ES2754269T3 (en) 2013-05-18 2020-04-16 Aduro Biotech Inc Compositions and Activation Methods of "Interferon Gene Stimulator-dependent" Signaling
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
US10925945B2 (en) 2014-10-13 2021-02-23 Providence Health & Services-Oregon Bacterial vaccines deficient in the 2-C-methyl-D-erythritol-4-phosphate pathway and methods of preparation and use thereof
EP3215139B1 (en) 2014-11-03 2020-08-19 Cerus Corporation Compositions and methods for improved car-t cell therapies
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
CA2383592A1 (en) * 1999-03-31 2000-10-05 Curagen Corporation 2384891 acids including open reading frames encoding polypeptides; orfx

Also Published As

Publication number Publication date
WO2002024739A3 (en) 2003-01-23
EP1320602A2 (en) 2003-06-25
WO2002024739A2 (en) 2002-03-28
CA2460014A1 (en) 2002-03-28
US20020150588A1 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
AU2001282890A1 (en) Immunosensor
AUPR395801A0 (en) Antibodies against cancer
AU2001262237A1 (en) Reflector
AU2002256895A1 (en) Anti-TRAIL-R antibodies
AU2002247304A1 (en) Anti-neovasculature preparations for cancer
AU2001234125A1 (en) Antibody library
AU2000267458A1 (en) Hypercomputer
AU2001220246A1 (en) Neckphone
AU2002365649A1 (en) Anti-dota antibody
AU2001239310A1 (en) Decahydro-isoquinolines
AU2001290860A1 (en) Spas-1 cancer antigen
AU2001252599A1 (en) Remedies for cancer
AU2001258349A1 (en) Bisacylguanidine
AU2002349543A1 (en) Tumor antigens
AU2001277711A1 (en) Remedies for cisplatin-tolerant cancer
AU2002307438A1 (en) Cancer-testis antigens
AU2001258924A1 (en) Microsatellite-aflp
AU6278300A (en) Tumor-associated antigen (r11)
AU2001242342A1 (en) Antiperspirants
AU2001240791A1 (en) Sequence
AU2001257325A1 (en) Cancer treatment
AU3283500A (en) Tumor-associated antigen
AU2001295582A1 (en) Tumour-related antigens
AU2001246864A1 (en) Hypotensors
AU2002221132A1 (en) Novel antibody